Author Correction: α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice

Chen, XinLiu, JieLiu, JieWang, Wen-JiaLai, Wen-JingLi, Shu-HuiDeng, Ya-FeiZhou, Jian-ZhiYang, Sheng-QianLiu, YingShou, Wei-NianCao, Da-YanLi, Xiao-Hui2023-08-012023-08-012022Chen X, Liu J, Liu J, et al. Author Correction: α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice. Acta Pharmacol Sin. 2022;43(7):1875-1878. doi:10.1038/s41401-021-00802-5https://hdl.handle.net/1805/34666This corrects the article "α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice" in volume 41 on page 1416.en-USPublisher Policyα-galactosylceramideOCHiNKT cellsIsoproterenolCancer immunotherapyCardiotoxicityOncocardiologyAuthor Correction: α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in miceArticle